"Serotonin Antagonists" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Drugs that bind to but do not activate serotonin receptors, thereby blocking the actions of serotonin or SEROTONIN RECEPTOR AGONISTS.
| Descriptor ID |
D012702
|
| MeSH Number(s) |
D27.505.519.625.850.850 D27.505.696.577.850.850
|
| Concept/Terms |
Serotonin Antagonists- Serotonin Antagonists
- 5-Hydroxytryptamine Antagonists
- 5 Hydroxytryptamine Antagonists
- Antagonists, 5-HT
- Antagonists, 5 HT
- Serotonin Receptor Blockers
- Blockers, Serotonin Receptor
- Receptor Blockers, Serotonin
- Antagonists, Serotonin
- Antiserotonergic Agents
- Agents, Antiserotonergic
- Serotonin Blockaders
- Blockaders, Serotonin
- Serotonin Receptor Antagonists
- Antagonists, Serotonin Receptor
- Receptor Antagonists, Serotonin
- 5-HT Antagonists
- 5 HT Antagonists
- Antagonists, 5-Hydroxytryptamine
- Antagonists, 5 Hydroxytryptamine
|
Below are MeSH descriptors whose meaning is more general than "Serotonin Antagonists".
Below are MeSH descriptors whose meaning is more specific than "Serotonin Antagonists".
This graph shows the total number of publications written about "Serotonin Antagonists" by people in this website by year, and whether "Serotonin Antagonists" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 1 | 0 | 1 |
| 1997 | 1 | 0 | 1 |
| 1998 | 2 | 1 | 3 |
| 1999 | 0 | 2 | 2 |
| 2001 | 0 | 1 | 1 |
| 2002 | 2 | 1 | 3 |
| 2003 | 1 | 0 | 1 |
| 2004 | 1 | 0 | 1 |
| 2005 | 1 | 1 | 2 |
| 2006 | 1 | 4 | 5 |
| 2007 | 2 | 0 | 2 |
| 2009 | 1 | 2 | 3 |
| 2010 | 2 | 1 | 3 |
| 2011 | 0 | 1 | 1 |
| 2013 | 1 | 0 | 1 |
| 2020 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Serotonin Antagonists" by people in Profiles.
-
High-resolution structures of multiple 5-HT3AR-setron complexes reveal a novel mechanism of competitive inhibition. Elife. 2020 10 16; 9.
-
Agonist- and antagonist-induced up-regulation of surface 5-HT3 A receptors. Br J Pharmacol. 2015 Aug; 172(16):4066-77.
-
The current status of the use of palonosetron. Expert Opin Pharmacother. 2013 Jul; 14(10):1281-4.
-
Pharmacological evaluation of SN79, a sigma (s) receptor ligand, against methamphetamine-induced neurotoxicity in vivo. Eur Neuropsychopharmacol. 2013 Aug; 23(8):960-71.
-
Control of breathing by raphe obscurus serotonergic neurons in mice. J Neurosci. 2011 Feb 09; 31(6):1981-90.
-
Clinical evaluation of two antiemetic combinations palonosetron dexamethasone versus ondansetron dexamethasone in chemotherapy of head and neck cancer. Singapore Med J. 2010 Nov; 51(11):871-5.
-
Cost-utility analysis of palonosetron-based therapy in preventing emesis among breast cancer patients. J Support Oncol. 2010 Nov-Dec; 8(6):242-51.
-
Prospective trial of efficacy and safety of ondansetron and fluoxetine in patients with obstructive sleep apnea syndrome. Sleep. 2010 Jul; 33(7):982-9.
-
State-dependent interactions between excitatory neuromodulators in the neuronal control of breathing. J Neurosci. 2010 Jun 16; 30(24):8251-62.
-
Palonosetron: a second generation 5-hydroxytryptamine 3 receptor antagonist. Expert Opin Drug Metab Toxicol. 2009 Dec; 5(12):1577-86.